JP5753336B2 - リン酸カルシウムセメントおよびそれを使用する方法 - Google Patents
リン酸カルシウムセメントおよびそれを使用する方法 Download PDFInfo
- Publication number
- JP5753336B2 JP5753336B2 JP2007523701A JP2007523701A JP5753336B2 JP 5753336 B2 JP5753336 B2 JP 5753336B2 JP 2007523701 A JP2007523701 A JP 2007523701A JP 2007523701 A JP2007523701 A JP 2007523701A JP 5753336 B2 JP5753336 B2 JP 5753336B2
- Authority
- JP
- Japan
- Prior art keywords
- calcium phosphate
- reactant
- composition
- phosphate
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000004568 cement Substances 0.000 title claims description 79
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 title claims description 69
- 238000000034 method Methods 0.000 title claims description 65
- 239000001506 calcium phosphate Substances 0.000 title claims description 56
- 229910000389 calcium phosphate Inorganic materials 0.000 title claims description 45
- 235000011010 calcium phosphates Nutrition 0.000 title claims description 45
- 239000000203 mixture Substances 0.000 claims description 121
- 239000000376 reactant Substances 0.000 claims description 69
- 239000002245 particle Substances 0.000 claims description 51
- 230000009969 flowable effect Effects 0.000 claims description 40
- 239000011575 calcium Substances 0.000 claims description 35
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 31
- 229910052791 calcium Inorganic materials 0.000 claims description 31
- 238000002156 mixing Methods 0.000 claims description 30
- 239000007788 liquid Substances 0.000 claims description 24
- 229910019142 PO4 Inorganic materials 0.000 claims description 23
- 239000012530 fluid Substances 0.000 claims description 22
- -1 calcium phosphate compound Chemical class 0.000 claims description 21
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 21
- 239000010452 phosphate Substances 0.000 claims description 21
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 12
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims description 8
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 8
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- 239000004927 clay Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 description 60
- 239000000047 product Substances 0.000 description 36
- 239000011800 void material Substances 0.000 description 25
- 239000000945 filler Substances 0.000 description 24
- 239000000463 material Substances 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 20
- 238000009472 formulation Methods 0.000 description 20
- 235000021317 phosphate Nutrition 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 210000000689 upper leg Anatomy 0.000 description 14
- 238000009826 distribution Methods 0.000 description 12
- 239000007787 solid Substances 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 239000010419 fine particle Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 239000011362 coarse particle Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 230000000399 orthopedic effect Effects 0.000 description 9
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 9
- 239000004115 Sodium Silicate Substances 0.000 description 8
- 238000002441 X-ray diffraction Methods 0.000 description 8
- 229910052586 apatite Inorganic materials 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 8
- 229910052911 sodium silicate Inorganic materials 0.000 description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 description 7
- 239000011707 mineral Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 6
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 6
- 206010017076 Fracture Diseases 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 239000002872 contrast media Substances 0.000 description 6
- 239000010459 dolomite Substances 0.000 description 6
- 229910000514 dolomite Inorganic materials 0.000 description 6
- 210000002997 osteoclast Anatomy 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000002411 adverse Effects 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 230000011164 ossification Effects 0.000 description 5
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical group [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 101100206195 Arabidopsis thaliana TCP2 gene Proteins 0.000 description 4
- 208000010392 Bone Fractures Diseases 0.000 description 4
- 101000666730 Homo sapiens T-complex protein 1 subunit alpha Proteins 0.000 description 4
- 101100536570 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CCT2 gene Proteins 0.000 description 4
- 102100038410 T-complex protein 1 subunit alpha Human genes 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 229920003086 cellulose ether Polymers 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000010072 bone remodeling Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical group [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000002805 bone matrix Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000012926 crystallographic analysis Methods 0.000 description 2
- 238000002447 crystallographic data Methods 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000010439 graphite Substances 0.000 description 2
- 229910002804 graphite Inorganic materials 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 238000010951 particle size reduction Methods 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- ZQZCOBSUOFHDEE-UHFFFAOYSA-N tetrapropyl silicate Chemical compound CCCO[Si](OCCC)(OCCC)OCCC ZQZCOBSUOFHDEE-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- HECLRDQVFMWTQS-UHFFFAOYSA-N Dicyclopentadiene Chemical compound C1C2C3CC=CC3C1C=C2 HECLRDQVFMWTQS-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 1
- 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- ARLZGEXVMUDUQZ-UHFFFAOYSA-N O.O.[Ca] Chemical compound O.O.[Ca] ARLZGEXVMUDUQZ-UHFFFAOYSA-N 0.000 description 1
- VHSSESVAKURAGI-UHFFFAOYSA-N OP(O)(=O)OP(O)(O)=O.OP(O)(=O)OP(O)(O)=O Chemical compound OP(O)(=O)OP(O)(O)=O.OP(O)(=O)OP(O)(O)=O VHSSESVAKURAGI-UHFFFAOYSA-N 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102000009890 Osteonectin Human genes 0.000 description 1
- 108010077077 Osteonectin Proteins 0.000 description 1
- 229920002984 Paramylon Polymers 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004111 Potassium silicate Substances 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 102000012005 alpha-2-HS-Glycoprotein Human genes 0.000 description 1
- 108010075843 alpha-2-HS-Glycoprotein Proteins 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- DNEHKUCSURWDGO-UHFFFAOYSA-N aluminum sodium Chemical compound [Na].[Al] DNEHKUCSURWDGO-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000000316 bone substitute Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 229910001576 calcium mineral Inorganic materials 0.000 description 1
- ZBZJARSYCHAEND-UHFFFAOYSA-L calcium;dihydrogen phosphate;hydrate Chemical compound O.[Ca+2].OP(O)([O-])=O.OP(O)([O-])=O ZBZJARSYCHAEND-UHFFFAOYSA-L 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000005586 carbonic acid group Chemical group 0.000 description 1
- 229920003064 carboxyethyl cellulose Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229940104869 fluorosilicate Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- RBLWMQWAHONKNC-UHFFFAOYSA-N hydroxyazanium Chemical compound O[NH3+] RBLWMQWAHONKNC-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003317 industrial substance Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 1
- 239000012705 liquid precursor Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 102000043253 matrix Gla protein Human genes 0.000 description 1
- 108010057546 matrix Gla protein Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- LXPCOISGJFXEJE-UHFFFAOYSA-N oxifentorex Chemical compound C=1C=CC=CC=1C[N+](C)([O-])C(C)CC1=CC=CC=C1 LXPCOISGJFXEJE-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000021401 pellet diet Nutrition 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- NNHHDJVEYQHLHG-UHFFFAOYSA-N potassium silicate Chemical compound [K+].[K+].[O-][Si]([O-])=O NNHHDJVEYQHLHG-UHFFFAOYSA-N 0.000 description 1
- 235000019353 potassium silicate Nutrition 0.000 description 1
- 229910052913 potassium silicate Inorganic materials 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- JTDPJYXDDYUJBS-UHFFFAOYSA-N quinoline-2-carbohydrazide Chemical compound C1=CC=CC2=NC(C(=O)NN)=CC=C21 JTDPJYXDDYUJBS-UHFFFAOYSA-N 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 230000009645 skeletal growth Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- UQMOLLPKNHFRAC-UHFFFAOYSA-N tetrabutyl silicate Chemical compound CCCCO[Si](OCCCC)(OCCCC)OCCCC UQMOLLPKNHFRAC-UHFFFAOYSA-N 0.000 description 1
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-O triethanolammonium Chemical compound OCC[NH+](CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-O 0.000 description 1
- XTIIITNXEHRMQL-UHFFFAOYSA-N tripotassium methoxy(trioxido)silane Chemical compound [K+].[K+].[K+].CO[Si]([O-])([O-])[O-] XTIIITNXEHRMQL-UHFFFAOYSA-N 0.000 description 1
- XYRAEZLPSATLHH-UHFFFAOYSA-N trisodium methoxy(trioxido)silane Chemical compound [Na+].[Na+].[Na+].CO[Si]([O-])([O-])[O-] XYRAEZLPSATLHH-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000005641 tunneling Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B11/00—Calcium sulfate cements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B11/00—Calcium sulfate cements
- C04B11/28—Mixtures thereof with other inorganic cementitious materials
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Ceramic Engineering (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Structural Engineering (AREA)
- Organic Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Curing Cements, Concrete, And Artificial Stone (AREA)
- Dental Preparations (AREA)
- Prostheses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/900,029 | 2004-07-26 | ||
| US10/900,029 US7175858B2 (en) | 2004-07-26 | 2004-07-26 | Calcium phosphate cements and methods for using the same |
| PCT/US2005/026369 WO2006014886A2 (en) | 2004-07-26 | 2005-07-25 | Calcium phosphate cements and methods for using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012150927A Division JP2012192212A (ja) | 2004-07-26 | 2012-07-04 | リン酸カルシウムセメントおよびそれを使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008507379A JP2008507379A (ja) | 2008-03-13 |
| JP2008507379A5 JP2008507379A5 (enExample) | 2008-07-31 |
| JP5753336B2 true JP5753336B2 (ja) | 2015-07-22 |
Family
ID=35657474
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007523701A Expired - Fee Related JP5753336B2 (ja) | 2004-07-26 | 2005-07-25 | リン酸カルシウムセメントおよびそれを使用する方法 |
| JP2012150927A Pending JP2012192212A (ja) | 2004-07-26 | 2012-07-04 | リン酸カルシウムセメントおよびそれを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012150927A Pending JP2012192212A (ja) | 2004-07-26 | 2012-07-04 | リン酸カルシウムセメントおよびそれを使用する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7175858B2 (enExample) |
| EP (1) | EP1771184B1 (enExample) |
| JP (2) | JP5753336B2 (enExample) |
| KR (1) | KR20070051845A (enExample) |
| AU (1) | AU2005269514B2 (enExample) |
| CA (1) | CA2574952C (enExample) |
| WO (1) | WO2006014886A2 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040081704A1 (en) | 1998-02-13 | 2004-04-29 | Centerpulse Biologics Inc. | Implantable putty material |
| US7820191B2 (en) * | 2000-04-28 | 2010-10-26 | Skeletal Kinetics, Llc | Calcium phosphate cements prepared from silicate solutions |
| US20020114795A1 (en) * | 2000-12-22 | 2002-08-22 | Thorne Kevin J. | Composition and process for bone growth and repair |
| US7166133B2 (en) | 2002-06-13 | 2007-01-23 | Kensey Nash Corporation | Devices and methods for treating defects in the tissue of a living being |
| US8221781B2 (en) * | 2003-04-11 | 2012-07-17 | Etex Corporation | Osteoinductive bone material |
| KR101218454B1 (ko) * | 2004-04-15 | 2013-01-04 | 에텍스 코포레이션 | 세팅 지연 칼슘 포스페이트 페이스트 |
| US8852240B2 (en) | 2004-10-25 | 2014-10-07 | Kieran Murphy, Llc | Methods and compositions for fostering and preserving bone growth |
| JP5582702B2 (ja) | 2005-09-09 | 2014-09-03 | アグノヴォス ヘルスケア,エルエルシー | 合成骨移植片代用セメントおよびそれから製造された製品 |
| US8147860B2 (en) | 2005-12-06 | 2012-04-03 | Etex Corporation | Porous calcium phosphate bone material |
| US7718616B2 (en) * | 2006-12-21 | 2010-05-18 | Zimmer Orthobiologics, Inc. | Bone growth particles and osteoinductive composition thereof |
| US7658940B2 (en) * | 2007-03-30 | 2010-02-09 | Skeletal Kinetics, Llc | Calcium phosphate cements comprising autologous bone |
| JP2010526064A (ja) * | 2007-04-27 | 2010-07-29 | ユニジーン・ラボラトリーズ・インコーポレーテッド | 骨組織の成長の育成および保存のための方法および組成物 |
| ES2400457T3 (es) | 2007-06-06 | 2013-04-10 | Innotere Gmbh | Material de implante a base de un cemento hidráulico y utilización del mismo |
| WO2009038191A1 (ja) * | 2007-09-20 | 2009-03-26 | Kyushu University, National University Corporation | 硬化性組成物 |
| EP2358651A2 (en) | 2008-11-12 | 2011-08-24 | Engqvist, Håkan | Hydraulic cements, methods and products |
| EP2352458A4 (en) * | 2008-12-04 | 2013-08-28 | Skeletal Kinetics Llc | TRICALCIUM PHOSPHATE GROWING PARTICLE COMPOSITIONS AND METHODS OF MAKING THE SAME |
| US8409538B2 (en) | 2008-12-04 | 2013-04-02 | Skeletal Kinetics Llc | Tricalcium phosphate coarse particle compositions and methods for making the same |
| US8673364B2 (en) | 2009-09-28 | 2014-03-18 | Skeletal Kinetics, Llc | Rapid setting high strength calcium phosphate cements comprising cyclodextrins |
| CN105125323B (zh) | 2010-03-10 | 2017-04-12 | 奥斯-Q公司 | 用于修复组织缺损的植入体和方法 |
| US20110243913A1 (en) * | 2010-04-06 | 2011-10-06 | Orthovita, Inc. | Biomaterial Compositions and Methods of Use |
| US9295695B2 (en) | 2010-04-30 | 2016-03-29 | Skeletal Kinetics, Llc | Temperature-insensitive calcium phosphate cements |
| US20120115780A1 (en) * | 2010-10-01 | 2012-05-10 | Delaney David C | Porogen Containing Calcium Phosphate Cement Compositions |
| WO2012062360A1 (en) | 2010-11-10 | 2012-05-18 | Stryker Trauma Gmbh | Polymeric bone foam composition and method |
| CA2817584C (en) | 2010-11-15 | 2018-01-02 | Zimmer Orthobiologics, Inc. | Bone void fillers |
| US9463046B2 (en) | 2011-08-22 | 2016-10-11 | Ossdsign Ab | Implants and methods for using such implants to fill holes in bone tissue |
| US20130066327A1 (en) | 2011-09-09 | 2013-03-14 | Håkan Engqvist | Hydraulic cement compositions with low ph methods, articles and kits |
| US8591645B2 (en) | 2011-09-09 | 2013-11-26 | Ossdsign Ab | Hydraulic cements with optimized grain size distribution, methods, articles and kits |
| US10207027B2 (en) | 2012-06-11 | 2019-02-19 | Globus Medical, Inc. | Bioactive bone graft substitutes |
| HK1216085A1 (zh) | 2012-12-14 | 2016-10-14 | Ossdsign Ab | 形成水泥的组合物、三斜磷钙石水泥、植入物及用於矫正骨缺损的方法 |
| US9220597B2 (en) | 2013-02-12 | 2015-12-29 | Ossdsign Ab | Mosaic implants, kits and methods for correcting bone defects |
| HK1217632A1 (zh) | 2013-02-12 | 2017-01-20 | Ossdsign Ab | 镶嵌型植人物、试剂盒和用於矫正骨缺损的方法 |
| US9539286B2 (en) | 2013-10-18 | 2017-01-10 | Globus Medical, Inc. | Bone grafts including osteogenic stem cells, and methods relating to the same |
| US9486483B2 (en) | 2013-10-18 | 2016-11-08 | Globus Medical, Inc. | Bone grafts including osteogenic stem cells, and methods relating to the same |
| US9579421B2 (en) | 2014-02-07 | 2017-02-28 | Globus Medical Inc. | Bone grafts and methods of making and using bone grafts |
| US9463264B2 (en) | 2014-02-11 | 2016-10-11 | Globus Medical, Inc. | Bone grafts and methods of making and using bone grafts |
| CN106999214B (zh) | 2014-08-14 | 2020-03-13 | 奥斯设计公司 | 镶嵌式植入物及其制造方法、支撑结构和植入物 |
| US11426489B2 (en) | 2015-06-10 | 2022-08-30 | Globus Medical, Inc. | Biomaterial compositions, implants, and methods of making the same |
| US10016529B2 (en) | 2015-06-10 | 2018-07-10 | Globus Medical, Inc. | Biomaterial compositions, implants, and methods of making the same |
| US11896736B2 (en) | 2020-07-13 | 2024-02-13 | Globus Medical, Inc | Biomaterial implants and methods of making the same |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5370097A (en) | 1976-12-03 | 1978-06-22 | Central Glass Co Ltd | Purifying method for crude sodium silicofluoride |
| JPS5395196A (en) | 1977-02-01 | 1978-08-19 | Central Glass Co Ltd | Production of purified sodium silicofluoride |
| JPS5654841A (en) | 1979-10-08 | 1981-05-15 | Mitsubishi Mining & Cement Co | Bone broken portion and filler for void portion and method of treating bone of animal using said filler |
| US4718910A (en) * | 1985-07-16 | 1988-01-12 | Klaus Draenert | Bone cement and process for preparing the same |
| US6005162A (en) | 1988-04-20 | 1999-12-21 | Norian Corporation | Methods of repairing bone |
| US5962028A (en) | 1988-04-20 | 1999-10-05 | Norian Corporation | Carbonated hydroxyapatite compositions and uses |
| US4990163A (en) | 1989-02-06 | 1991-02-05 | Trustees Of The University Of Pennsylvania | Method of depositing calcium phosphate cermamics for bone tissue calcification enhancement |
| US5281265A (en) | 1992-02-03 | 1994-01-25 | Liu Sung Tsuen | Resorbable surgical cements |
| US5698253A (en) * | 1992-12-11 | 1997-12-16 | Dekker; Enno E. J. | Dimethyl-cyclohexanecarboxylic acid esters in perfumery |
| US5522893A (en) | 1993-03-12 | 1996-06-04 | American Dental Association Health Foundation | Calcium phosphate hydroxyapatite precursor and methods for making and using the same |
| JP3773254B2 (ja) | 1993-07-22 | 2006-05-10 | ノリアン コーポレイション | 貯蔵安定性の部分中和化酸組成物及び利用 |
| US5525148A (en) | 1993-09-24 | 1996-06-11 | American Dental Association Health Foundation | Self-setting calcium phosphate cements and methods for preparing and using them |
| CA2143733A1 (en) | 1994-03-02 | 1995-09-03 | Yoshikazu Umezu | Alpha-tricalcium phosphate ceramic and production method thereof |
| US6586006B2 (en) * | 1994-08-04 | 2003-07-01 | Elan Drug Delivery Limited | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
| US5496399A (en) | 1994-08-23 | 1996-03-05 | Norian Corporation | Storage stable calcium phosphate cements |
| US5569442A (en) * | 1994-11-04 | 1996-10-29 | Norian Corporation | Reactive tricalcium phosphate compositions and uses |
| US6027742A (en) | 1995-05-19 | 2000-02-22 | Etex Corporation | Bioresorbable ceramic composites |
| US6132463A (en) | 1995-05-19 | 2000-10-17 | Etex Corporation | Cell seeding of ceramic compositions |
| US5795922A (en) * | 1995-06-06 | 1998-08-18 | Clemson University | Bone cement composistion containing microencapsulated radiopacifier and method of making same |
| ZA9711732B (en) * | 1996-12-31 | 1998-12-28 | Quadrant Holdings Cambridge | Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery |
| US20020009464A1 (en) * | 1997-07-03 | 2002-01-24 | Camilo Colaco | Modified glycosides, compositions comprised thereof and methods of use thereof |
| JP2001518359A (ja) | 1997-10-07 | 2001-10-16 | ドクトル.ハー.ツェー.ロベルト マシーズ スティフツング | 外科用水硬セメント |
| US6352722B1 (en) * | 1997-12-23 | 2002-03-05 | Quadrant Holdings Cambridge Limited | Derivatized carbohydrates, compositions comprised thereof and methods of use thereof |
| DE19812713A1 (de) | 1998-03-24 | 1999-09-30 | Merck Patent Gmbh | Verfahren zur Herstellung von mineralisierten Kollagenfibrillen und deren Verwendung als Knochenersatzwerkstoff |
| US6730322B1 (en) * | 1998-04-30 | 2004-05-04 | Acusphere, Inc. | Matrices formed of polymer and hydrophobic compounds for use in drug delivery |
| US5968253A (en) | 1998-07-31 | 1999-10-19 | Norian Corporation | Calcium phosphate cements comprising antimicrobial agents |
| JP2001106638A (ja) | 1999-08-05 | 2001-04-17 | Takeda Chem Ind Ltd | 骨形成促進物質徐放性ペースト |
| EP1235599B1 (en) | 1999-12-09 | 2003-07-23 | Dr.h.c. Robert Mathys Stiftung | Brushite hydraulic cement stabilized with a magnesium salt |
| FR2805747B1 (fr) | 2000-03-01 | 2003-03-14 | Teknimed | Procede de preparation d'un materiau pateux phosphocalcique injectable en vue de former un biomateriau apatitique et application chirurgicale ou dentaire |
| US6375935B1 (en) | 2000-04-28 | 2002-04-23 | Brent R. Constantz | Calcium phosphate cements prepared from silicate solutions |
| US6547866B1 (en) | 2000-10-30 | 2003-04-15 | Howmedica Osteonics Corp. | Porous calcium phosphate cement |
| US6840961B2 (en) | 2001-12-21 | 2005-01-11 | Etex Corporation | Machinable preformed calcium phosphate bone substitute material implants |
| CA2609772A1 (en) | 2005-06-07 | 2006-12-14 | The Lutheran University Association, Inc, D/B/A Valparaiso University | Quantum-dot cellular automata methods and devices |
-
2004
- 2004-07-26 US US10/900,029 patent/US7175858B2/en not_active Expired - Lifetime
-
2005
- 2005-07-25 JP JP2007523701A patent/JP5753336B2/ja not_active Expired - Fee Related
- 2005-07-25 EP EP05781881.7A patent/EP1771184B1/en not_active Expired - Lifetime
- 2005-07-25 US US11/189,555 patent/US8419803B2/en not_active Expired - Fee Related
- 2005-07-25 WO PCT/US2005/026369 patent/WO2006014886A2/en not_active Ceased
- 2005-07-25 AU AU2005269514A patent/AU2005269514B2/en not_active Ceased
- 2005-07-25 CA CA2574952A patent/CA2574952C/en not_active Expired - Fee Related
- 2005-07-25 KR KR1020077002081A patent/KR20070051845A/ko not_active Abandoned
-
2012
- 2012-07-04 JP JP2012150927A patent/JP2012192212A/ja active Pending
-
2013
- 2013-03-13 US US13/800,694 patent/US10022471B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP1771184A2 (en) | 2007-04-11 |
| JP2008507379A (ja) | 2008-03-13 |
| WO2006014886A3 (en) | 2007-04-05 |
| AU2005269514B2 (en) | 2010-08-19 |
| AU2005269514A1 (en) | 2006-02-09 |
| JP2012192212A (ja) | 2012-10-11 |
| CA2574952C (en) | 2015-01-27 |
| US20060018974A1 (en) | 2006-01-26 |
| US8419803B2 (en) | 2013-04-16 |
| KR20070051845A (ko) | 2007-05-18 |
| CA2574952A1 (en) | 2006-02-09 |
| US10022471B2 (en) | 2018-07-17 |
| WO2006014886A2 (en) | 2006-02-09 |
| US20070189951A1 (en) | 2007-08-16 |
| EP1771184B1 (en) | 2016-07-13 |
| US7175858B2 (en) | 2007-02-13 |
| EP1771184A4 (en) | 2011-11-16 |
| US20130273118A1 (en) | 2013-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5753336B2 (ja) | リン酸カルシウムセメントおよびそれを使用する方法 | |
| JP5351369B2 (ja) | 注射用骨ミネラル代替物質用組成物 | |
| US9827346B2 (en) | Rapid setting high strength calcium phosphate cements comprising cyclodextrins | |
| AU2010226979B2 (en) | Rapid setting calcium phosphate cements | |
| US8246736B2 (en) | Tricalcium phosphate coarse particle compositions and methods for making the same | |
| US20050257714A1 (en) | Orthopedic cements comprising a barium apatite contrast agent | |
| US9889223B2 (en) | Temperature-insensitive calcium phosphate cements | |
| KR20070021224A (ko) | 고속 세팅 인산 칼슘 시멘트 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080611 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080611 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110422 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20110422 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110422 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110527 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110826 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111128 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120406 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120921 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141204 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141209 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141224 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150305 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150305 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150522 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5753336 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |